SecBot SecBot
SECBOTREPLAY Home › Report › VIR

VIR · Vir Biotechnology filed a definitive proxy statement (DEFA14A)…

Vir Biotechnology, Inc. · DEFA14A filed Apr 16, 2026 at 08:49 ET

At the news

NEUTRALIMPACT 3/10

DEFA14A filed Apr 16, 2026 at 08:49 ET

Vir Biotechnology filed a definitive proxy statement (DEFA14A) following the recent departure of its Chief Medical Officer, Mark Eisner. The filing is routine and does not indicate any material changes or shareholder disputes.

  • Filed a DEFA14A proxy statement
  • Follows the recent departure of Chief Medical Officer Mark Eisner
  • No activist campaign or shareholder dispute mentioned
  • Filing is routine and procedural

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access